Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 28.3% in March

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 7,700 shares, a growth of 28.3% from the February 28th total of 6,000 shares. Based on an average daily volume of 12,600 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.1% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

Armata Pharmaceuticals Trading Down 9.7 %

Shares of NYSEAMERICAN ARMP traded down $0.14 during trading hours on Wednesday, hitting $1.30. 16,976 shares of the stock were exchanged, compared to its average volume of 10,818. Armata Pharmaceuticals has a one year low of $1.32 and a one year high of $4.11. The company has a market cap of $47.03 million, a P/E ratio of -0.79 and a beta of 0.87.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.